Joint Reconstruction Devices Market By Product Type (Knee Reconstruction Devices, Hip Reconstruction Devices, Shoulder Reconstruction Devices, Small-Joint Reconstruction Devices); By Material (Metal-Based Implants, Ceramic-Based Implants, Polymer-Based Implants); By End User (Hospitals, Ambulatory Surgical Centers, Specialty Orthopedic Clinics); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Joint Reconstruction Devices Market: Procedure Capacity, Outpatient Economics, and Robotics Reshape Competition

The Global Joint Reconstruction Devices Market was valued at USD 24.66 billion in 2025 and is projected to reach USD 39.86 billion by 2032, growing at a CAGR of 7.1%, according to Strategic Market Research.

 

Numerous joint reconstruction devices have FDA approval, including established knee systems like ATTUNE and Persona, hip systems such as the G7 Acetabular System and Taperloc stems, and robotic platforms like DePuy Synthes VELYS and CUVIS-joint for improved surgical precision. The pipeline is shifting toward innovation, including iodine-coated antimicrobial implants, smart sensor-enabled devices that provide real-time post-surgical performance data, and meniscal spacers progressing toward IDE clinical trials.

 

Surgical Conversion Determines Revenue from the Osteoarthritis Population

Approximately 33 million U.S. adults had osteoarthritis in national data covering 2017 through March 2020. WHO estimated that 528 million people were living with osteoarthritis globally in 2019, including 365 million with knee osteoarthritis. Knee disease therefore represents the largest quantified joint-specific population connected to reconstruction procedures.

Hip fractures add a less discretionary source of demand. The United States recorded 290,130 hip-fracture hospitalizations among adults aged 65 and older in 2019. A global analysis estimated 14.2 million incident hip fractures during the same year. Selected femoral-neck fractures require hemiarthroplasty or total hip replacement, converting an acute hospital admission directly into implant demand.

Osteonecrosis, rheumatoid arthritis, post-traumatic damage, and failed implants create smaller but commercially valuable procedure groups. Revision surgery can require additional components, specialist instruments, and bone-loss products when implants loosen, become infected, wear, fracture, dislocate, or lose stability.

 

Procedure Capacity Sets the Near-Term Revenue Ceiling

More than one million total hip and total knee arthroplasties are performed annually in the United States. Shoulder, ankle, elbow, wrist, finger, and other reconstruction procedures are excluded from that figure, making it a conservative measure of total national demand.

The American Joint Replacement Registry contained more than 4.6 million procedures when its 2025 annual report was released. AAOS now describes the registry as covering more than five million procedures from hospitals, ambulatory surgical centers, and private practices across all 50 states, the District of Columbia, and Puerto Rico. The growing database allows hospitals and payers to compare revision rates, implant survivorship, patient outcomes, and practice variation using a national evidence base.

International procedure data show how surgical capacity changes the addressable market. EU countries performed nearly one million hip replacements and approximately 680,000 knee replacements in 2022. OECD countries averaged 198 hip replacements and 156 knee replacements per 100,000 population in 2023.

High-volume countries support stronger economics for robotics, revision systems, direct sales teams, and surgeon education because each hospital can generate more implant cases. Lower-volume countries may have substantial untreated demand, but suppliers must first address reimbursement, surgeon supply, tender pricing, and distribution.

Partial knee replacement illustrates the difference between clinical relevance and segment scale. AJRR analyzed 101,468 unicompartmental knee procedures performed from 2012 through 2024. Partial replacement has accounted for less than 5% of U.S. knee procedures since 2015, while 93% of cases were completed by surgeons performing no more than 15 procedures annually.

 

Outpatient Policy Is Expanding Access While Tightening Procedure Economics

CMS increased 2026 hospital outpatient payment rates by 2.6% for facilities meeting quality-reporting requirements. The agency also began a three-year phase-out of the inpatient-only list by removing 285 mostly musculoskeletal procedures. Revised criteria added 289 procedures to the ASC Covered Procedures List, together with 271 codes removed from the inpatient-only list.

Zimmer Biomet, Smith+Nephew, and Stryker are building commercial programs around these outpatient requirements. Zimmer Biomet partnered with Getinge in July 2025 to combine implants and robotics with operating-room equipment and facility infrastructure for ASC customers. Smith+Nephew has expanded its ASC strategy around facility development, financing, sterile processing, and clinical support. Stryker markets its implants and Mako platform through a dedicated ASC offering.

 

Robotics Is Being Used to Protect Implant Share

Stryker, Zimmer Biomet, Smith+Nephew, and DePuy Synthes are developing multiple robotic formats because hospitals and ASCs differ in procedure volume, available space, surgeon preference, and capital budgets. Large robotic arms, handheld systems, and software-led navigation allow suppliers to defend implant share across different operating environments.

Stryker commercially launched Mako RPS in the United States in July 2026. The handheld robotic power system works with the Triathlon Total Knee System and expands Mako beyond robotic-arm-assisted procedures. More than 2.5 million Mako procedures had been performed across 47 countries by the time of the launch.

The handheld format gives Stryker access to facilities that may not support the cost or physical footprint of a large robotic arm. Stryker can preserve the link between Mako and Triathlon while offering a lower-infrastructure option to hospitals and ASCs.

Smith+Nephew completed the first clinical cases with CORI XT in June 2026 across knee and shoulder arthroplasty. The handheld platform is intended to support partial, total, and revision knee replacement as well as anatomic and reverse shoulder procedures.

Smith+Nephew’s revenue mix confirms the commercial role of enabling technology. The company had more than 1,100 CORI systems installed worldwide by the end of 2025. Other Reconstruction revenue, which includes CORI systems and consumables, increased 33.8% during the year. Growth in robotics capital, service, and disposable revenue substantially outpaced the company’s core implant categories.

Zimmer Biomet completed its acquisition of Monogram Technologies in October 2025. The transaction added CT-based robotic capabilities to a portfolio in which ROSA was approaching 2,000 installations worldwide. Zimmer Biomet can now address surgeons seeking imageless robotics, CT-based planning, and future autonomous workflows rather than depending on one platform architecture.

DePuy Synthes launched VELYS Hip Navigation with AI assistance in June 2026. Company validation reported landmark-identification workflow time of 2.27 minutes compared with 5.33 minutes for the manual process, representing a 57% reduction. DePuy also agreed to acquire development and commercialization rights to Gemtrack radiofrequency tracking technology across shoulder, hip, and knee navigation and robotic applications.

 

Outcomes Evidence Is Entering Procurement Decisions

AJRR introduced device-specific cumulative revision data for unicompartmental knee components in its 2025 supplement. Hospitals can now compare component survivorship across major manufacturers rather than relying only on surgeon preference or supplier presentations.

Lower revision rates can reduce repeat operations, readmissions, rehabilitation costs, and reputational exposure. Strong registry performance can therefore protect formulary access and support premium pricing. Weak or incomplete evidence gives procurement teams greater leverage to negotiate discounts or standardize around better-documented systems.

Leading suppliers are connecting implants with digital planning and outcome measurement. Zimmer Biomet is expanding robotics and data-enabled care management, Smith+Nephew links CORI placements with service and consumable revenue, and DePuy is adding AI-supported hip navigation and tracking technology across several joints. These investments shift competition away from isolated implant features and toward measurable procedure efficiency and long-term performance.

 

Joint Reconstruction Devices Market Segment Analysis and Forecast

Strategic Market Research’s segment estimates allocate the approved USD 24.66 billion market value across product types, implant materials, end users, and regions. The forecasts account for procedure mix, care-setting migration, supplier investment, implant utilization, and differences in healthcare access.

By Product Type

Knee reconstruction devices accounted for an estimated 45.0% of revenue in 2025, equivalent to approximately USD 11.10 billion. The segment is projected to reach USD 17.94 billion by 2032, expanding at a CAGR of 7.1%.

Knee systems retain the largest revenue position because knee osteoarthritis represents the largest quantified joint-specific disease population. Total knee arthroplasty also accounts for substantially more procedures than partial replacement. AJRR data showing partial knee at less than 5% of U.S. knee procedures confirms that manufacturer revenue remains concentrated in total knee systems.

Stryker’s Mako RPS is tied to Triathlon, Smith+Nephew is extending CORI XT across primary and revision knee procedures, and Zimmer Biomet acquired Monogram to expand its robotic knee offering. These investments allow suppliers to defend knee implant share through capital placement, planning software, instruments, service, and recurring consumables rather than competing only on implant price.

Hip reconstruction devices represented an estimated 36.0% of the market in 2025, generating approximately USD 8.88 billion. Revenue is forecast to reach USD 13.78 billion by 2032 at a CAGR of 6.5%.

Hip growth is slightly below the total market because replacement rates are already high in several mature countries. Osteoarthritis, osteonecrosis, fractures, revision surgery, and implant instability continue to support a large procedure base. Nearly one million hip replacements were performed across EU countries in 2022, while U.S. fracture hospitalizations add a substantial acute-care population.

DePuy’s AI-assisted VELYS Hip Navigation, Stryker’s Mako hip platform, and Zimmer Biomet’s ROSA and digital portfolio are shifting competition toward planning efficiency and account standardization. Suppliers that support both hip and knee workflows can spread technology costs across more procedures and negotiate broader hospital contracts.

 

Shoulder reconstruction devices held an estimated 13.0% market share in 2025, equal to approximately USD 3.21 billion. The segment is projected to reach USD 5.64 billion by 2032 at a CAGR of 8.4%.

Shoulder is the fastest-growing major product segment because reverse shoulder arthroplasty has expanded reconstruction beyond conventional arthritis cases to patients with cuff-tear arthropathy, tendon deficiency, fractures, and complex joint destruction. The segment also starts from a smaller installed base than hip or knee, leaving greater scope for surgeon conversion and account expansion.

Smith+Nephew has extended CORI XT into anatomic and reverse shoulder procedures. Enovis has expanded through the DJO and LimaCorporate portfolios, while Medacta reported 43.4% growth in its extremities category during 2025. Multiple supplier investments support an above-market forecast rather than relying on one product launch.

Small-joint reconstruction devices covering the elbow, wrist, ankle, and related joints accounted for an estimated 6.0% share in 2025, generating approximately USD 1.48 billion. Revenue is forecast to reach USD 2.50 billion by 2032 at a CAGR of 7.8%.

Lower procedure volumes restrict scale, but specialist systems can generate higher revenue per case where deformity, bone loss, or previous trauma requires procedure-specific implants. Small-joint portfolios also help suppliers consolidate relationships with specialist orthopedic centers.

Enovis, Zimmer Biomet, and other extremity suppliers use ankle, elbow, wrist, and finger systems to broaden account coverage. The segment will not approach hip or knee volumes, but it strengthens suppliers with established extremity sales teams and reduces dependence on mature large-joint categories.

 

By Material

Metal-based implants accounted for an estimated 67.0% share in 2025, equivalent to USD 16.52 billion. Revenue is projected to reach USD 26.19 billion by 2032 at a CAGR of 6.8%.

Titanium and cobalt-chromium alloys remain central to femoral components, tibial trays, stems, shells, and revision constructs. Established manufacturing capacity, clinical evidence, and compatibility with complex revision systems preserve the segment’s dominant position.

Metal-based implants will add approximately USD 9.67 billion in annual revenue through 2032, although their market share is expected to decline from 67.0% to about 65.7%. Faster growth in ceramic bearings will cause the modest share reduction rather than declining metal demand. Revision procedures will continue to support metal consumption because modular stems, cones, augments, and fixation components increase material use per case.

 

Ceramic-based implants represented an estimated 20.0% share in 2025, generating USD 4.93 billion. The segment is forecast to reach USD 8.45 billion by 2032 at a CAGR of 8.0%.

Ceramic adoption is strongest in bearing applications where wear performance and reduced metal exposure influence implant selection, particularly among younger or more active hip-replacement patients. Ceramic revenue is projected to increase to 21.2% of the market by 2032.

Premium pricing will depend on long-term evidence rather than material claims alone. Hospitals are more likely to accept higher ceramic costs where registry data support lower wear or longer implant survival. Suppliers unable to document those benefits will face pressure to price ceramic components closer to conventional alternatives.

 

Polymer-based implants accounted for an estimated 13.0% share in 2025, equal to USD 3.21 billion. Revenue is projected to reach USD 5.22 billion by 2032 at a CAGR of 7.2%.

Polyethylene bearings and related components are used across hip, knee, shoulder, and smaller-joint systems, linking polymer demand closely to total procedure growth. Supplier differentiation depends on wear resistance and revision performance rather than the use of polymer itself.

Product-specific installed-use records can support commercial positioning, but registry-based outcomes will carry more weight in hospital contracts. Manufacturers must connect material improvements with measurable reductions in wear, revision risk, or lifetime procedure cost.

 

By End User

Hospitals held an estimated 69.0% market share in 2025, generating USD 17.02 billion. Hospital revenue is projected to reach USD 25.92 billion by 2032 at a CAGR of 6.2%.

Hospitals retain the largest share because revision surgery, fracture-related arthroplasty, medically complex patients, and procedures requiring extensive postoperative support remain concentrated in these facilities. Major hospitals also have sufficient procedure volume to support large robotic installations and broad inventory commitments.

Hospital share is forecast to decline to about 65.0% by 2032 as appropriate primary procedures migrate to outpatient facilities. Hospitals will nevertheless remain the principal buyers of revision systems, premium robotics, and complex reconstruction products.

Ambulatory surgical centers accounted for an estimated 23.0% of revenue in 2025, equivalent to USD 5.67 billion. The segment is forecast to reach USD 10.71 billion by 2032 at a CAGR of 9.5%, increasing its share to approximately 26.9%.

ASC growth is supported by CMS site-of-care policy and supplier investment in outpatient infrastructure. The addition of hundreds of procedures to outpatient and ASC pathways expands the addressable facility base, while Zimmer Biomet, Smith+Nephew, and Stryker are building dedicated ASC programs.

ASCs favor compact robotics, fewer instrument trays, flexible financing, and predictable procedure times. Suppliers that adapt hospital-scale offerings to these economics can capture procedures migrating from inpatient facilities. Vendors that retain complex inventory and capital models risk losing share even when their implants remain clinically established.

Specialty orthopedic clinics represented an estimated 8.0% market share in 2025, generating USD 1.97 billion. Revenue is projected to reach USD 3.23 billion by 2032 at a CAGR of 7.3%.

Clinics influence diagnosis, referrals, surgeon preference, preoperative planning, and postoperative follow-up, although surgery may be completed in an affiliated hospital or ASC. Independent orthopedic groups are gaining purchasing influence through ASC ownership and participation in bundled-care arrangements.

Suppliers that establish relationships at the clinic level can influence implant selection before patients reach the operating facility. Digital planning and recovery platforms extend that relationship into preoperative and postoperative care, strengthening surgeon loyalty and account retention.

 

By Geography

North America accounted for an estimated 42.0% of global revenue in 2025, equivalent to USD 10.36 billion. The regional market is projected to reach USD 16.09 billion by 2032 at a CAGR of 6.5%.

More than one million hip and knee arthroplasties are performed annually in the United States, while AJRR has accumulated more than five million procedures. High utilization supports revision demand, direct sales infrastructure, robotic-system economics, and outcomes-based contracting.

North America’s share is projected to moderate to approximately 40.4% by 2032 as Asia-Pacific grows faster. The region will retain the largest revenue position because premium implants, robotic utilization, outpatient migration, and revision procedures support higher revenue per case.

 

Europe represented an estimated 28.0% share in 2025, generating USD 6.90 billion. Revenue is forecast to reach USD 10.52 billion by 2032 at a CAGR of 6.2%.

EU countries performed nearly one million hip replacements and approximately 680,000 knee replacements in 2022. The established procedure base creates recurring opportunities in primary implants, revisions, and enabling technologies.

Public tenders and hospital budget controls limit unsupported premium pricing. Suppliers must justify higher prices through survivorship evidence, lower revision risk, dependable service, or measurable workflow savings. Europe’s global share is projected to decline to about 26.4% by 2032 as faster-growing regions expand procedure capacity.

 

Asia-Pacific held an estimated 22.0% share in 2025, equivalent to USD 5.43 billion. Revenue is projected to reach USD 9.94 billion by 2032 at a CAGR of 9.0%, raising the region’s share to approximately 24.9%.

Aging populations, private hospital investment, surgeon training, and wider access to orthopedic procedures support the fastest regional growth. Market conversion will remain uneven because reimbursement, specialist capacity, and patient affordability differ sharply across countries.

Premium urban hospitals can support robotics and imported implant systems. Public and price-sensitive facilities require lower-cost portfolios, local manufacturing, and dependable distributor support. Global suppliers will need tiered pricing and stronger regional service to convert the underlying disease burden into sustainable procedure revenue.

 

Latin America accounted for an estimated 5.0% share in 2025, generating USD 1.23 billion. Revenue is projected to reach USD 2.09 billion by 2032 at a CAGR of 7.8%.

Private hospital development and expansion of specialist orthopedic services support procedure growth. Currency volatility, import costs, and uneven public reimbursement limit premium implant adoption. Distributor-led suppliers with simplified portfolios and lower capital requirements are better positioned than companies relying only on expensive robotic bundles.

 

The Middle East and Africa represented an estimated 3.0% share in 2025, equal to USD 0.74 billion. Revenue is forecast to reach USD 1.22 billion by 2032 at a CAGR of 7.4%.

Gulf healthcare investment supports premium implants and robotics in selected medical centers. Limited surgical capacity, procurement funding, and distribution infrastructure constrain adoption across much of Africa. Regional growth will remain concentrated in countries able to fund specialist orthopedic facilities and maintain reliable implant supply.

 

Competitive Growth Is Concentrated in Robotics, Shoulder, and Extremities

Large manufacturers retain advantages in inventory depth, hospital contracting, revision coverage, field service, and capital investment. Specialist suppliers are nevertheless growing faster in selected categories.

Enovis reported 10% growth in reconstructive sales during 2025, including 8% organic growth. Medacta increased hip revenue by 9.4%, knee revenue by 17.8%, and extremities revenue by 43.4%. Smith+Nephew’s Other Reconstruction revenue, including CORI systems and consumables, increased 33.8%.

These results place the strongest growth in enabling technology, shoulder and extremity systems, and focused challenger portfolios rather than mature conventional implants alone. Specialist companies can gain share where they combine surgeon support with differentiated products and faster commercial execution. Large suppliers retain the advantage when hospitals purchase implants, robotics, revision coverage, and data services under one agreement.

Johnson & Johnson’s planned separation of DePuy Synthes could increase competitive pressure further. A stand-alone orthopedic company would have more direct control over acquisitions, capital allocation, robotics investment, and portfolio development. Zimmer Biomet’s Monogram acquisition and the continued expansion of Stryker and Smith+Nephew robotics indicate that large manufacturers are already preparing for more aggressive platform competition.

 

Market Outlook

Knee reconstruction, metal-based implants, hospitals, and North America generated the largest segment revenues in 2025. Shoulder devices, ceramic implants, ambulatory surgical centers, and Asia-Pacific are forecast to expand faster than the total market through 2032.

The projected 7.1% CAGR depends on higher procedure throughput, outpatient migration, a larger revision population, shoulder growth, and wider adoption of implant-linked robotics. Suppliers that improve operating efficiency or reduce total episode costs will capture a larger share of the USD 15.20 billion in additional annual revenue expected by 2032.

Hospitals and ASCs are standardizing around complete reconstruction programs rather than isolated implants. Companies that combine primary and revision systems with robotics, efficient instruments, financing, facility support, and outcomes evidence can retain accounts and defend pricing. Implant-only suppliers face greater substitution risk as procurement shifts toward complete service-line economics and measurable performance.

 

Joint Reconstruction Devices Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 24.66 Billion
Revenue Forecast in 2032	USD 39.86 Billion
Overall Growth Rate	CAGR of 7.1% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Product Type, By Material, By End User, By Geography
By Product Type	Knee Reconstruction Devices, Hip Reconstruction Devices, Shoulder Reconstruction Devices, Small-Joint Reconstruction Devices
By Material	Metal-Based Implants, Ceramic-Based Implants, Polymer-Based Implants
By End User	Hospitals, Ambulatory Surgical Centers, Specialty Orthopedic Clinics
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, China, Japan, South Korea, India, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	Rising hip and knee reconstruction procedure volumes, growing osteoarthritis and revision-surgery burden, migration of eligible procedures to outpatient facilities, wider adoption of robotic and navigation-assisted surgery, increasing use of outcomes evidence in implant procurement
Customization Option	Available upon request